Free tool
FAERS Monitor: Reclast
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022080 or its brand name (Reclast, Zoledronic Acid). Reports on generic versions are filed under their own applications.
Reports
40,714
Serious
35,240
87% of reports
Hospitalization
11,750
Death reported
5,181
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- arthralgia3,285
- pain3,218
- fatigue2,877
- nausea2,875
- pyrexia2,875
- osteonecrosis of jaw2,775
- death2,522
- headache2,431
- diarrhoea2,335
- vomiting2,090
- asthenia2,015
- myalgia1,908
- off label use1,775
- pain in extremity1,708
- dyspnoea1,669
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 40 |
| 2005 | 92 |
| 2006 | 108 |
| 2007 | 281 |
| 2008 | 853 |
| 2009 | 1,339 |
| 2010 | 1,535 |
| 2011 | 2,241 |
| 2012 | 2,416 |
| 2013 | 996 |
| 2014 | 809 |
| 2015 | 1,331 |
| 2016 | 1,465 |
| 2017 | 1,673 |
| 2018 | 2,318 |
| 2019 | 2,676 |
| 2020 | 2,708 |
| 2021 | 2,705 |
| 2022 | 2,796 |
| 2023 | 3,043 |
| 2024 | 3,317 |
| 2025 | 3,556 |
| 2026 | 2,415 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,013,445 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| osteonecrosis of jawSignal | 2,775 | 65.1 | 62.7 | 155,684 |
| myalgiaSignal | 1,908 | 5.9 | 5.6 | 7,647 |
| pyrexiaSignal | 2,875 | 4.3 | 4.2 | 7,393 |
| arthralgiaSignal | 3,285 | 4.1 | 4.0 | 7,809 |
| pain in extremitySignal | 1,708 | 3.0 | 2.9 | 2,304 |
| astheniaSignal | 2,015 | 2.8 | 2.7 | 2,320 |
| painSignal | 3,218 | 2.7 | 2.6 | 3,571 |
| vomitingSignal | 2,090 | 2.3 | 2.2 | 1,566 |
| headacheSignal | 2,431 | 2.0 | 1.9 | 1,260 |
| fatigue | 2,877 | 1.9 | 1.8 | 1,295 |
| nausea | 2,875 | 1.9 | 1.8 | 1,225 |
| diarrhoea | 2,335 | 1.9 | 1.8 | 974 |
| dyspnoea | 1,669 | 1.5 | 1.5 | 308 |
| death | 2,522 | 1.5 | 1.5 | 457 |
| off label use | 1,775 | 1.0 | 1.0 | 4 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.